| abstract |
the disclosure provides new transmucosal and subcutaneous pharmaceutical compositions composed of 1- (4-fluoro-phenyl) -4 - ((6br, 10as) -3-methyl-2,3,6b, 9,10,10ahexahidro- 1h, 7h- pyrido [3 ', 4': 4,5] pyrrolo [1,2,3-de] quinoxalin-8-yl) -butan-1-one or 1- (4-fluoro-phenyl) -4 - ((6br , 10as) -2,2-d2-3-methyl-2,3,6b, 9,10,10a-hexahydro-1h, 7hpirido [3 ', 4': 4,5] pyrrole [1,2,3- de] quinoxalin-8-yl) -butan-1-one or composed of 1- (4-fluoro-phenyl) -4 - ((6br, 10as) -1,1,2,2-d4-3-methyl- 2,3,6b, 9,10,10a-hexahydro-1h, 7hpirido [3 ', 4': 4,5] pyrrolo [1,2,3-de] quinoxalin-8-yl) -butan-1-one , on a free base, in co-crystallized or saline form, together with methods of manufacturing and using them. |